MabPlex International

Overview
Biosimilars?
Product stageSegments
Growth
?
Contract Development and Manufacturing Organizations
?

MabPlex International, Ltd. is a Contract Development and Manufacturing Organization (CDMO) specializing in biologics. The company offers comprehensive services for monoclonal antibody (mAb) and antibody-drug conjugate (ADC) therapeutics, including cell line development, process characterization, conjugation optimization, cGMP manufacturing, and aseptic fill finish solutions. Founded in 2013, MabPlex operates from three locations: two in China (Yantai and Shanghai) and one in the US (San Diego, California). The company's facilities span over 60,000 square meters, housing nine monoclonal antibody Drug Substance production lines, two Antibody-drug Conjugate Drug Substance production lines, and formulation lines for both mAb and ADC products. MabPlex's services are designed to accelerate clinical trials and support market launches for its clients.

In September 2018, MabPlex inaugurated its M2 manufacturing facility in Yantai, China, expanding its total manufacturing operations to approximately 750,000 square feet, with 400,000 square feet dedicated to cGMP execution. The M2 facility features six independent cell culture suites, each capable of supporting up to two single-use bioreactors with volumes up to 2,000 liters, four independent purification suites, and a cGMP warehouse. In February 2020, MabPlex further expanded its capabilities by launching two new 2,000-liter cell culture production lines, with plans to add two more by the end of March 2020. This expansion demonstrated the company's experience in operating different types of reactors and its ability to meet diverse customer demands flexibly.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
4059 Clipper Ct Fremont CA USA
Founded year:
2013
Employees:
501-1,000
IPO status:
Private
Total funding:
USD 129.7 mn
Last Funding:
USD 70.7 mn (Series B; Jun 2020)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.